These two variables were used to develop a score that distinguished three groups of patients with a 74%, 23%, and 7% probability of response to EPO with or without G‐CSF, depending on whether none, one, or two of these risk factors were present, in a study that did not include only lower‐risk patients with MDS [25]. The gene discussed is EPO; the disease is myelodysplastic syndrome.